P2RY12 and chronic kidney disease: Similar to the result of previous studies, this study revealed that replacing clopidogrel with a potent oral P2Y12 inhibitor such as prasugrel or ticagrelor provides beneficial clinical outcomes in CKD patients, as implied by a substantially lowered all-cause mortality risk, MACE, and MI without elevated bleeding risks [15].